FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Biovest | BiovaxID

BiovaxID gets EMA orphan status

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


The European Medicines Agency has designated Biovest International's BiovaxID vaccine as an orphan medicinal product for mantle cell lymphoma. The personalized cancer vaccine has received orphan drug status for the treatment of mantle cell lymphoma and follicular lymphoma in both the U.S. and EU.

With orphan drug status, Biovest has 10 years of marketing exclusivity for both diseases once the vaccine receives EMA approval. Two Phase II trials and one Phase III trial have already been completed.

"We believe mantle cell lymphoma is an ideal indication for BiovaxID to potentially provide significant clinical benefit for patients," explains Carlos Santos, Biovest's senior VP, Product Development & Regulatory Affairs, in a release. "Our clinical data, as reported last December at the American Society of Hematology (ASH) Annual Meeting, suggests that BiovaxID-treated patients who express a certain type of protein isotype called IgM on their lymphoma cells are much more likely to remain cancer-free longer after achieving a remission following induction therapy. Virtually all mantle cell lymphoma patients express this IgM isotype, so we look forward to advancing BiovaxID for the treatment of this aggressive blood cancer."

- see the Biovest release

Related Article:
Biovest wins orphan drug status for cancer vax

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Biovest   BiovaxID  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.